
AstraZeneca's Alexion accused of extending Soliris monopoly through sham patents in new suit
With biosimilars to AstraZeneca’s blockbuster rare blood disease med Soliris recently available in the U.S., nonprofit health plan EmblemHealth is taking a shot at the company and its alleged patent misuse in court. Soliris (eculizumab) was first approved …